Pergolide as primary therapy for macroprolactinomas.

摘要: The objective of this study is to determine whether pergolide therapy an effective modality for the de novo treatment patients with macroprolactinomas. Twenty-two consecutive macroprolactinomas were included in and followed prospectively. These 16 men 6 women whom pregnancy was not concern. Pergolide administered once or twice a day depending on patient's preference. Ten received 0.1 mg daily as maintenance regimen others dose ranged from 0.05 0.5 mg. Eight reported minor but tolerable side effects. One patient had be switched cabergoline because intolerable nausea. After mean 12 months (range, 3–36), PRL levels declined 3,135 ng/ml 126–31,513) 50 (3–573), representing suppression 88% 0–99). became normal 15 decreased 25–40 3 others. tumor volume shrinkage 25% greater 19 (86%), 50% 17 (77%), 75% 10 (45%). Visual abnormalities reversible after all 1 initially abnormal formal visual testing. Two out 4 premenopausal did normalize persistent oligomenorrhea. Testosterone low 14 at presentation normalized therapy. We conclude that safe, inexpensive, generally well-tolerated dopamine agonist In these specific populations, may become first-line